Munc13 Is a Molecular Target of Bryostatin 1
Open Access
- 3 June 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 58 (27) , 3016-3030
Abstract
Bryostatin 1 is a natural macrolide shown to improve neuronal connections and enhance memory in mice. Its mechanism of action is largely attributed to the modulation of novel and conventional protein kinase C (PKC) by binding to their regulatory C1 domains. Munc13-1 is a C1 domain containing protein that shares common endogenous and exogenous activators with novel and conventional PKC subtypes. Given the essential role of Munc13-1 in the priming of synaptic vesicles and neuronal transmission overall, we explored the potential interaction between bryostatin 1 and Munc13-1. Our results indicate that in vitro bryostatin 1 binds to both the isolated C1 domain of Munc13-1 (Ki=8.07±0.90 nM) and the full-length Munc13-1 protein (Ki= 0.45±0.04 nM). Furthermore, confocal microscopy and immunoblot analysis demonstrated that in intact HT22 cells bryostatin 1 mimics the actions of phorbol esters, a previously established class of Munc13-1 activators, and induces plasma membrane translocation of Munc13-1, a hallmark of its activation. Consistently, bryostatin 1 had no effect on the Munc13-1H567K construct that is insensitive to phorbol esters. Effects of bryostatin 1 on the other Munc13 family members, ubMunc13-2 and bMunc13-2, resembled those of Munc13-1 for translocation. Lastly, we observed an increased expression of Munc13-1 following 24 h incubation with bryostatin 1 in both HT22 and primary mouse hippocampal cells. This study characterizes Munc13-1 as a molecular target of bryostatin 1. Considering the crucial role of Munc13-1 in neuronal function, current findings provide strong support for the potential role of Munc13s in the actions of bryostatin 1.Keywords
Funding Information
- National Cancer Institute (Z1A BC 005270)
- National Institute on Alcohol Abuse and Alcoholism (1R01 AA022414-01A1)
This publication has 68 references indexed in Scilit:
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s DiseaseJournal of Alzheimer’s Disease, 2018
- Inhibition of Inflammation, Suppression of Matrix Metalloproteinases, Induction of Neurogenesis, and Antioxidant Property Make Bryostatin-1 a Therapeutic Choice for Multiple SclerosisFrontiers in Pharmacology, 2018
- Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer’s Disease Phase IIa and Expanded Access TrialsJournal of Alzheimer’s Disease, 2017
- Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer’s DiseaseCurrent Alzheimer Research, 2015
- Bryostatin-1 Restores Hippocampal Synapses and Spatial Learning and Memory in Adult Fragile X MiceThe Journal of Pharmacology and Experimental Therapeutics, 2014
- Bryostatin-1 vs. TPPB: Dose-Dependent APP Processing and PKC-α, -δ, and -ε Isoform Activation in SH-SY5Y Neuronal CellsJournal of Molecular Neuroscience, 2012
- The Chemistry and Biology of the Bryostatins: Potential PKC Inhibitors in Clinical DevelopmentCurrent Medicinal Chemistry, 2012
- Bryostatin-1: Pharmacology and Therapeutic Potential as a CNS DrugCNS Drug Reviews, 2006
- Chemistry and clinical biology of the bryostatinsBioorganic & Medicinal Chemistry, 2000
- The Bryostatins1991